(PharmaNewsWire.Com, April 13, 2017 ) According to the report Global Psoriasis Drugs Market, published by Market Data Forecast, the global market is projected to reach USD 10.8 billion with a CAGR of 7.30% from USD 7.6 billion in 2016.
Psoriasis is noncommunicable, inflammatory skin condition that alter the life cycle of skin cells by speeding up the cell building process on the surface of the skin. Rapid development of cells produces thick, silver scales, and makes the skin red, dry, flaky, and itchy. The various types of psoriasis are vulgaris, guttate, inverse, pustular, palmoplantar, erythrodermic, nail, and scalp psoriasis. Currently, no permanent cure is available for the disease, however preventative measures can be adopted to slow down the growth of cells on the surface of the skin. Psoriasis can be treated either with pharmaceuticals or biopharmaceuticals therapies through topical and systemic process. These medications when administered, either by applying on the skin, or consumed orally, or through injections, specifically block parts of immune system process by targeting Tumour Necrosis Factor, Phosphodiesterase Type 4, Interleukin, among others.
The growth of Psoriasis Drugs market is majorly driven by factors such as rising healthcare expenditure, boost in psoriasis Research and Development investment, introduction of novel and more efficient drug, and increasing demand of psoriasis medicines in emerging economies. Additionally, psoriasis requires long term treatment as it can reoccur after the first line treatment, thereby increasing sales revenue. Also, with the availability of better diagnostic devices will result in building confidence in people, thereby resulting in increasing treatment-seeking population. People seeking treatment for Psoriasis are also showing interest in combination therapies. A combination therapy of Topical and Systemic (Alefacept, etanercept, and others taken with methotrexate) have shown better results in patient. Expected entry of late-stage pipeline products (Xeljanz and the biosimilar adalimumab by Pfizer) are anticipated to accelerate the growth of the product.
Segmentation: Based on Drug Type Pharmaceuticals Biopharmaceuticals Based on Route of Administration Topical Systemic Oral Intravenous Others Based on Target Tumour Necrosis Factor (TNF) Phosphodiesterase Type 4 (PDE4) Interleukin Others Geographical Segmentation: North America Europe Asia-Pacific Latin America Middle East and Africa
The major companies dominating the global Antiviral Drugs market are Johnson & Johnson (USA), Novartis International AG (Switzerland), Roche Holding AG (Switzerland), Pfizer (USA), Merck and Co. Inc (USA), GlaxoSmithKline plc (United Kingdom), AstraZeneca AB (United Kingdom), Gilead Sciences (USA), and Abbott Laboratories (USA).
About us: Market Data Forecast is a firm working in the areas of market research and business intelligence. We have rich experience in research across major industry segments like Healthcare, Agriculture, Food & Beverages etc. and we cater to the needs of both individual and corporate clients. Our research services contribute to key business areas like business process improvement, key decision making and developing appropriate corporate strategy. We are truly committed to our clients and other stakeholders for providing customized research services of the highest quality all the while being an organisation thats trusted for its integrity, respected for its accountability, and admired for its excellence, by both clients and competitors alike.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
